The antiphospholipid syndrome and Tregs

Autoimmunity Reviews

Volumn 13, Issue 6, 2014, Pages 697-698

  Staub, Henrique Luiz ^a   Dal Ben, Ester Rosári Raphaelli ^a   Bauer, Moisés Evandro ^a  

^a PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

BETA2 GLYCOPROTEIN 1; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 23; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA;

ADOPTIVE TRANSFER; ANTIPHOSPHOLIPID SYNDROME; AUTOIMMUNITY; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL CONTACT; DENDRITIC CELL; ENDOTHELIAL DYSFUNCTION; HUMAN; IMMUNE RESPONSE; IMMUNOREGULATION; IMMUNOTHERAPY; INSULIN DEPENDENT DIABETES MELLITUS; LETTER; LYMPHOCYTE COUNT; MEMORY T LYMPHOCYTE; MONONUCLEAR CELL; NONHUMAN; PATHOPHYSIOLOGY; PHENOTYPE; REGULATORY MECHANISM; REGULATORY T LYMPHOCYTE; REMISSION; RHEUMATOID ARTHRITIS; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE SUBPOPULATION; THROMBOSIS;

ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; HUMANS; PHENOTYPE; T-LYMPHOCYTES, REGULATORY;

EID: 84896546778     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2013.08.004     Document Type: Letter

References (19)

1. Giannakopoulos B., Krilis S.A. The pathogenesis of the antiphospholipid syndrome. N Engl J Med 2013, 368:1033-1044.
2. Broder A., Chan J.J., Putterman C. Dendritic cells: an important link between antiphospholipid antibodies, endothelial dysfunction, and atherosclerosis in autoimmune and non-autoimmune diseases. Clin Immunol 2013, 146:197-206.
3. Popovic-Kuzmanovic D., Novakovic I., Stojanovich L., Aksentijevich I., Zogovic N., Tovilovic G., et al. Increased activity of interleukin-23/interleukin-17 cytokine axis in primary antiphospholipid syndrome. Immunobiology 2013, 218:186-191.
4. Ohkura N., Kitagawa Y., Sakaguchi S. Development and maintenance of regulatory T cells. Immunity 2013, 38:414-423.
5. Miyara M., Gorochov G., Ehrenstein M., Musset L., Sakaguchi S., Amoura Z. Human FoxP3+ regulatory T cells in systemic autoimmune diseases. Autoimmun Rev 2011, 10:744-755.
6. Bernard F., Romano A., Granel B. Regulatory T cells and systemic autoimmune diseases: systemic lupus erythematosus, rheumatoid arthritis, primary Sjögren's syndrome. Rev Med Interne 2010, 31:116-127.
7. Papo T., Piette J.C., Legac E., Frances C., Grenot P., Debre P., et al. T lymphocyte subsets in primary antiphospholipid syndrome. J Rheumatol 1994, 21:2242-2245.
8. Blank M., Krause I., Buskila D., Teitelbaum D., Kopolovic J., Afek A., et al. Bromocriptine immunomodulation of experimental SLE and primary antiphospholipid syndrome via induction of nonspecific T suppressor cells. Cell Immunol 1995, 162:114-122.
9. Carbone J., Gallego A., Lanio N., Navarro J., Orera M., Aguaron A., et al. Quantitative abnormalities of peripheral blood distinct T, B, and natural killer cell subsets and clinical findings in obstetric antiphospholipid syndrome. J Rheumatol 2009, 36:1217-1225.
10. Bansal A.S., Bajardeen B., Shehata H., Thum M.Y. Recurrent miscarriage and autoimmunity. Expert Rev Clin Immunol 2011, 7:37-44.
11. Dal Ben E.R., do Prado C.H., Baptista T.S., Bauer M.E., Staub H.L. Decreased levels of circulating CD4+CD25+Foxp3+ regulatory T cells in patients with primary antiphospholipid syndrome. J Clin Immunol 2013, 33:876-879.
12. Dal Ben E.R.R., do Prado C.H., Baptista T.S.A., Bauer M.E., Staub H.L. Patients with systemic lupus erythematosus and secondary antiphospholipid syndrome have decreased numbers of circulating CD4+CD25+Foxp3+ Treg and CD3-CD19+ B cells. Braz J Rheumatol 2013, [In Press].
13. Xiao J., Zhu F., Liu X., Xiong J. Th1/Th2/Th17/Treg expression in cultured PBMCs with antiphospholipid antibodies. Mol Med Rep 2012, 6:1035-1039.
14. Torres-Aguilar H., Blank M., Kivity S., Misgav M., Luboshitz J., Pierangeli S.S., et al. Tolerogenic dendritic cells inhibit antiphospholipid syndrome derived effector/memory CD4+ T cell response to β2GPI. Ann Rheum Dis 2012, 71:120-128.
15. Cousens L.P., Tassone R., Mazer B.D., Ramachandiran V., Scott D.W., De Groot A.S. Tregitope update: mechanism of action parallels IVIg. Autoimmun Rev 2013, 12:436-443.
16. Horwitz D.A., Gray J.D., Zheng S.G. The potential of human regulatory T cells generated ex vivo as a treatment for lupus and other chronic inflammatory diseases. Arthritis Res 2002, 4:241-246.
17. Weigert O., von Spee C., Undeutsch R., Kloke L., Humrich J.Y., Riemekasten G. CD4+Foxp3+ regulatory T cells prolong drug-induced disease remission in (NZBxNZW) F1 lupus mice. Arthritis Res Ther 2013, 15:R35.
18. Marek-Trzonkowska N., Mysliwiec M., Dobyszuk A., Grabowska M., Techmanska I., Juscinska J., et al. Administration of CD4+CD25highCD127-regulatory T cells preserves β-cell function in type 1 diabetes in children. Diabetes Care 2012, 35:1817-1820.
19. Sakaguchi S., Vignali D.A., Rudensky A.Y., Niec R.E., Waldmann H. The plasticity and stability of regulatory T cells. Nat Rev Immunol 2013, 13:461-467.